Effect of liraglutide treatment on mitigation of hearing damage induced by multiday repeated high-intensity blasts.
J Acoust Soc Am · 2025
Last updated 2026-05-28In a study on chinchillas exposed to repeated high-intensity blasts, liraglutide—a GLP-1 drug—reduced hearing damage when given before or after the blasts. Pre-blast treatment lowered hearing threshold shifts on both blast days, while post-blast treatment only helped on the second day. Ears treated after blasts also showed better hearing responses and more healthy nerve cells compared to untreated ears.
AI summary of the abstract below.
| Journal | J Acoust Soc Am, 2025 |
|---|---|
| Citations | 0 |
| Molecules | liraglutide |
Abstract
Exposures to blasts impair hearing, despite the protection of earplugs. Liraglutide showed therapeutic effects against hearing damage induced by single-day blasts. However, the effect of liraglutide on auditory damage caused by multiday repeated blasts remains unknown. Chinchillas protected by earplugs were exposed to three blasts at 15-25 psi on day 1, followed by an identical exposure on day 4. Animals were assigned to pre-blast treatment, post-blast treatment, or blast control groups based on the timing of liraglutide administration relative to the day 1 blasts. Auditory brainstem response (ABR), middle latency response, and distortion product otoacoustic emission were measured at multiple time points following the blast. Spiral ganglion neuron density was assessed histologically at the end of the study. The blast control group showed 20-30 dB ABR threshold shift across frequencies on both days 1 and 4. Pre-blast treatment reduced threshold shifts on days 1 and 4, while post-blast treatment was effective only on day 4. Post-blast treated ears showed higher ABR wave amplitudes and greater spiral ganglion neuron density after day 4 blasts compared to blast control ears. The liraglutide treatment significantly mitigated the blast-induced temporary damage when the blasts occurred during the treatment period.
Verbatim abstract via PubMed 40853101 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.